Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Immune checkpoint blockade, targeting PD-L1/PD-1 interactions, is a key cancer therapy.
• Many patients do not respond to checkpoint inhibitors, highlighting the need to understand PD-L1 regulation.
• Tumor PD-L1 expression is a biomarker, but its regulatory mechanisms remain incompletely understood.

Purpose of the Study:

• To investigate the role of the eukaryotic translation initiation complex eIF4F in regulating PD-L1 expression.
• To explore the potential of targeting eIF4F components as an anticancer immunotherapy strategy.

Main Methods:

• Investigated the regulation of interferon-γ-induced PD-L1 surface expression on cancer cells.
• Analyzed the role of the eIF4F complex in translating the mRNA of signal transducer and activator of transcription 1 (STAT1).
• Correlated eIF4F complex formation with immunotherapy response in human melanoma patients.
• Evaluated the effects of pharmacological inhibition of eIF4A on antitumor immunity and PD-L1 levels.

Main Results:

• The eIF4F complex regulates interferon-γ-induced PD-L1 surface expression by controlling STAT1 mRNA translation.
• eIF4F complex formation positively correlates with response to immunotherapy in human melanoma.
• Pharmacological inhibition of eIF4A leads to potent immune-mediated antitumor effects through PD-L1 downregulation.

Conclusions:

• eIF4F is a critical regulator of PD-L1 expression in cancer cells.
• eIF4A inhibitors, currently in development, demonstrate potential as novel cancer immunotherapies by downregulating PD-L1 and enhancing anti-tumor immunity.